Literature DB >> 15056998

Evaluation of re-challenge in patients with suspected lidocaine allergy.

E Amsler1, A Flahault, P Mathelier-Fusade, S Aractingi.   

Abstract

BACKGROUND: Lidocaine is an anaesthetic agent used worldwide in various clinical specialties. Although lidocaine hypersensitivity is very rare, clinicians frequently encounter patients with such an alleged diagnosis. Using a questionnaire, we evaluated the results of re-challenge with lidocaine, the gold standard for assessing hypersensitivity reactions in patients who claim to be allergic to this drug.
METHODS: A detailed questionnaire was sent to members of the French Dermatological Society, targeting the management of patients claiming lidocaine intolerance. After analysis and recall of doubtful episodes, 199 re-challenges were made. True lidocaine hypersensitivity was finally demonstrated in only 1 patient.
CONCLUSIONS: The results of this study demonstrate that patients claiming to be allergic to lidocaine are usually not, their symptoms corresponding in most cases to a vasovagal episode. Re-challenge is safe and may constitute an easy and cheap alternative to skin testing. This should be performed in specialized centres except in case of a vasovagal episode. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056998     DOI: 10.1159/000076482

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  Anaphylactic reactions to local anesthetics in dental practice: a nationwide French retrospective study.

Authors:  E Hascoët; J Mahé; H Meillard; H Théophile; A Cloitre; P Lesclous
Journal:  Clin Oral Investig       Date:  2021-08-24       Impact factor: 3.573

Review 2.  Allergy to Local Anesthetics is a Rarity: Review of Diagnostics and Strategies for Clinical Management.

Authors:  Shirley Jiang; Monica Tang
Journal:  Clin Rev Allergy Immunol       Date:  2022-04-28       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.